Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Argentina
Bangladesh
Belize
Bolivia
Botswana
Brazil
Bulgaria
Cambodia
Colombia
Czech Republic
Dominican Repu..
Egypt
El Salvador
Germany
Guatemala
Honduras
India
Indonesia
Iran
Jamaica
Japan
Lebanon
Malaysia
Mexico
Nicaragua
Nigeria
North Macedonia
Panama
Paraguay
Peru
Philippines
Portugal
Slovakia
South Africa
Thailand
USA
Ukraine
Venezuela
Zimbabwe

Feedback
Home   COVID-19 treatment studies  COVID-19 treatment studies  COVID-19 studies   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Global ivermectin adoption for COVID-19: 36%
Ivermectin is currently used for about 28% of the world's population. Countries where COVID-19 mortality is close to zero may not have incentive to adopt treatments. When excluding these countries, ivermectin adoption is about 36%. We excluded countries where the cumulative mortality over the preceding month was less than 1 in 1 million, according to the data at https://ourworldindata.org/). For the estimated population coverage, isolated use, some regions, mixed usage, and many regions use a factor of 0.05, 0.25, 0.5, and 0.75 respectively. Please send us corrections/updates.
References
Argentina - mixed usage - Jan 26, 2021
Bangladesh - country-wide adoption
Belize - country-wide adoption - used for serious cases - Dec 18, 2020
Bolivia - country-wide adoption
Botswana - mixed usage
Brazil - used in some regions - Jan 26, 2021
Bulgaria - country-wide adoption
Cambodia - country-wide adoption
Colombia - used in many regions
Czech Republic - isolated use - authorized, but reportedly almost no use
Dominican Republic - country-wide adoption - Sep 30, 2020
Egypt - country-wide adoption - Nov 30, 2020
El Salvador - country-wide adoption
Germany - isolated use - Dec 31, 2020
Guatemala - country-wide adoption - Jan 23, 2021
Honduras - country-wide adoption - Apr 23, 2020
India - used in many regions - 4/28/21 recommended by ICMR, usage in some states differs, DGHS disagrees
Indonesia - mixed usage
Iran - mixed usage - now manufacturing their own ivermectin, but the level of usage is unclear
Jamaica - isolated use - authorized for off-label use, availability delayed
Japan - used in some regions - May 18, 2020
Lebanon - country-wide adoption - Jan 27, 2021
Malaysia - isolated use
Mexico - mixed usage - Dec 29, 2020
Nicaragua - country-wide adoption - Jan 25, 2021
Nigeria - used in many regions
North Macedonia - mixed usage - Jan 15, 2021
Panama - country-wide adoption
Paraguay - used in some regions
Peru - used in some regions - was widely used but later restricted, a study shows 14x reduction in excess deaths when used and 13x increase when restricted - May 8, 2020
Philippines - isolated use
Portugal - used in some regions
Slovakia - mixed usage - while approved, press has been divided, censorship is common, and access is limited but improving - Jan 27, 2021
South Africa - mixed usage - may be prescribed without section 21 approval from 3/17/21, compounding allowed from 4/7/21 - Jan 27, 2021
Thailand - isolated use
USA - used in some regions - Oct 31, 2020
Ukraine - mixed usage
Venezuela - country-wide adoption
Zimbabwe - country-wide adoption - Jan 28, 2021
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit